Prosthetic joint infections - Pipeline Review, H1 2018 - Product Image

Prosthetic joint infections - Pipeline Review, H1 2018

  • ID: 4576116
  • Report
  • 44 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • ContraFect Corp
  • Motif Bio Plc
  • Nabriva Therapeutics plc
  • Telephus Medical LLC
  • MORE
Prosthetic joint infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic joint infections - Pipeline Review, H1 2018, provides an overview of the Prosthetic joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

Report Highlights:

This latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Unknown stages are 1, 6 and 1 respectively.

Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic joint infections (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prosthetic joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prosthetic joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prosthetic joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AmpliPhi Biosciences Corp
  • ContraFect Corp
  • Motif Bio Plc
  • Nabriva Therapeutics plc
  • Telephus Medical LLC
  • MORE
Introduction

Report Coverage

Prosthetic joint infections - Overview

Prosthetic joint infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Prosthetic joint infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prosthetic joint infections - Companies Involved in Therapeutics Development

AmpliPhi Biosciences Corp

ContraFect Corp

Motif Bio Plc

Nabriva Therapeutics plc

Telephus Medical LLC

Prosthetic joint infections - Drug Profiles

(tobramycin + vancomycin SR) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABSA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-296 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTF-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNP-2092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prosthetic joint infections - Dormant Projects

Prosthetic joint infections - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Prosthetic joint infections, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Prosthetic joint infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018

Prosthetic joint infections - Pipeline by ContraFect Corp, H1 2018

Prosthetic joint infections - Pipeline by Motif Bio Plc, H1 2018

Prosthetic joint infections - Pipeline by Nabriva Therapeutics plc, H1 2018

Prosthetic joint infections - Pipeline by Telephus Medical LLC, H1 2018

Prosthetic joint infections - Dormant Projects, H1 2018

Prosthetic joint infections - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Prosthetic joint infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AmpliPhi Biosciences Corp
  • ContraFect Corp
  • Motif Bio Plc
  • Nabriva Therapeutics plc
  • Telephus Medical LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll